All In Biotech

Drug Trial Radar · NCT05278208

Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors

Phase I/II Study of Lutathera in Patients With Recurrent and/or Progressive High-Grade Central Nervous System Tumors and Meningiomas That Demonstrate Uptake on DOTATATE PET

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

65

Planned (sponsor's estimate)

Start

Nov 21, 2022

Primary completion

Nov 2028

Study completion Nov 2033

Sponsor

Lead sponsor
Nationwide Children's HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 4 years, up to 39 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety and efficacy of Lutathera (177Lu-DOTATATE) in patients with progressive or recurrent High-Grade Central Nervous System (CNS) tumors and meningiomas that demonstrate uptake on DOTATATE PET. The drug will be given intravenously once every 8 weeks for a total of up to 4 doses over 8 months in patients aged 4 to \<12 years (Phase I) or 12 to \</=39 years (Phase II) to test its safety and efficacy, respectively. Funding Source - FDA OOPD (grant number FD-R-0532-01)

Conditions

  • High Grade Glioma
  • Meningioma
  • Embryonal Tumor
  • Medulloblastoma
  • Anaplastic Ependymoma
  • Recurrent Diffuse Intrinsic Pontine Glioma
  • Recurrent Malignant Glioma
  • Recurrent Medulloblastoma
  • Recurrent Primary Central Nervous System Neoplasm
  • Refractory Diffuse Intrinsic Pontine Glioma
  • Refractory Malignant Glioma
  • Refractory Medulloblastoma
  • Refractory Primary Central Nervous System Neoplasm

Interventions

  • LUTATHERA® (Lutetium Lu 177 dotatate)Drug

    Lutathera: IV administration maximum dose of 200 mCi once every 8 weeks (one cycle) for total of 4 cycles (8 months)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Estimate MTD of Lutathera in pediatric CNS patients 4 to <12 yearsTime frame: up to 8 months
  2. Estimate RP2D of Lutathera in pediatric CNS patients 4 to <12 yearsTime frame: up to 8 months
  3. Calculate the incidence of treatment related adverse events as assessed by CTCAE v5.0 in pediatric (4 to <12 yo) CNS patients treated with LutatheraTime frame: up to 2 months
  4. Assess PFS of Lutathera in CNS patients 12 to </=39 yearsTime frame: up to 6 months

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Children's Hospital Colorado

    Aurora, Colorado · Withdrawn

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio · Recruiting

  • Nationwide Children's Hospital

    Columbus, Ohio · Recruiting

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.